Document is current
Any future updates will be listed below
-
Authors
Fu, Yu
Yang, Bin
Cui, Yaoyuan
Hu, Xingyuan
Li, Xi
Lu, Funian
Qin, Tianyu
Zhang, Li
Hu, Zhe https://orcid.org/0000-0002-2724-6778
Guo, Ensong
Fan, Junpeng
Xiao, Rourou
Li, Wenting
Qin, Xu
Hu, Dianxing
Peng, Wenju
Liu, Jingbo
Wang, Beibei
Mills, Gordon B
Chen, Gang
Sun, Chaoyang https://orcid.org/0000-0003-2469-1638
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01587703 at ClinicalTrials.govnct03059147 at ClinicalTrials.govDocuments that mention this clinical trial
BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
https://doi.org/10.1136/jitc-2022-006070
Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications
https://doi.org/10.1136/gutjnl-2025-336317
nct02419417 at ClinicalTrials.govDocuments that mention this clinical trial
BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
https://doi.org/10.1136/jitc-2022-006070
nct01949883 at ClinicalTrials.govDocuments that mention this clinical trial
BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
https://doi.org/10.1136/jitc-2022-006070
nct03068351 at ClinicalTrials.govDocuments that mention this clinical trial
BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
https://doi.org/10.1136/jitc-2022-006070
nct02259114 at ClinicalTrials.govDocuments that mention this clinical trial
BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
https://doi.org/10.1136/jitc-2022-006070
Documents that mention this clinical trial
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
https://doi.org/10.1136/gutjnl-2016-312539
BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
https://doi.org/10.1136/jitc-2022-006070
-
Funding
Funding for this research was provided by:
Chaoyang Sun (2022YFC2704200;2022YFC2704202;81974408)
Gang Chen (82073259; 2020BCA067)
Ensong Guo (82002762)
- License Information
